Effects of Hospice Care for Terminal Head and Neck Cancer Patients: A Nationwide Population-Based Matched Cohort Study.

Head and neck cancer was the fourth-most common cause of cancer death among Taiwanese men in 2018. Hospice care has been proven to reduce the use of invasive medical interventions and expenditures in caring for cancer patients. This study examined the effects of hospice care for terminal head and neck cancer patients. A matched cohort study was used to compare the use of invasive interventions and expenditures among hospice care and nonhospice care patients. The investigated patients consisted of patients who died of head and neck cancer in Taiwan from 2004 to 2013 and were included in the Registry for Catastrophic Illness Patients in Taiwan and the Taiwan National Health Research Insurance Database. A total of 45,948 terminal head and neck cancer patients were identified, and 9883 patients remained in each group after matching for comorbidities. After that matching, the rates of intensive care unit admission (23.9% vs. 38.94%,  < 0.0001), endotracheal intubation (10.05% vs. 31.32%,  < 0.0001), cardiopulmonary resuscitation (2.93% vs. 20.18%,  < 0.0001), defibrillation (0.51% vs. 4.36%.  < 0.0001), ventilator use (21.92% vs. 46.47%,  < 0.0001), blood transfusion (71.25% vs. 73.45%,  = 0.006), and hemodialysis (1.06% vs. 3.26%.  < 0.0001) were significantly lower in the hospice group than the nonhospice group, although the rates of parenteral nutrition for the two groups were similar (7.74% vs. 7.97%,  = 0.5432). The mean medical expenditure per person in the six months before death was 460,531 New Taiwan Dollar (NTD) for the nonhospice group and 389,079 NTD for those provided hospice care for more than three months, which was the lowest amount among various hospice enrollment durations. Hospice care can effectively reduce the use of invasive medical interventions in caring for terminal head and neck cancer patients and may improve their quality of death. Moreover, hospice care enrollment for more than three months can save on unnecessary medical expenditures for terminal head and neck cancer patients.